BRIEF published on 12/11/2025 at 23:05, 7 months 19 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 7 months 19 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 7 months 19 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 8 months 11 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 8 months 11 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 8 months 11 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 8 months 17 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 8 months 17 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 8 months 17 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 9 months 20 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 07/31/2026 at 01:39, 4 hours 5 minutes ago Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 5 hours 59 minutes ago Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 6 hours 43 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 6 hours 44 minutes ago Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:52, 10 hours 52 minutes ago First Canadian Graphite annonce des résultats de prospection de graphite à haute teneur jusqu'à 43,4 % Cg au projet Lac Guéret Sud
Published on 07/31/2026 at 00:00, 5 hours 44 minutes ago EQS-Adhoc: VIB Vermögen AG: Agreements on the restructuring of financial liabilities of BRANICKS Group AG signed, incl. commitment for a € 60 mn financing for VIB Vermögen AG
Published on 07/30/2026 at 23:48, 5 hours 55 minutes ago BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 23:46, 5 hours 57 minutes ago EQS-Adhoc: Branicks Group AG: BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 22:05, 7 hours 39 minutes ago Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Published on 07/30/2026 at 22:05, 7 hours 39 minutes ago Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod
Published on 07/30/2026 at 18:15, 11 hours 28 minutes ago Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:15, 11 hours 28 minutes ago Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 07/30/2026 at 18:05, 11 hours 38 minutes ago Electricité de Strasbourg - Avis de mise à disposition de l'information financière du 1er semestre 2026
